VIVITROL will be manufactured by Alkermes and commercialised by Janssen-Cilag, an affiliate company of Cilag GmbH International.
Alkermes will receive manufacturing revenues and a royalty based on product sales as well as retain exclusive development and marketing rights to VIVITROL in all markets outside the US, Russia and other countries in the CIS. In the US, VIVITROL is commercialised primarily by Cephalon Inc. Reportedly, VIVITROL is the first and only once-monthly, extended-release injectable medication for the treatment of alcohol dependence and was approved by the US Food and Drug Administration in April 2006.
Comments on this story may be sent to admin@m2.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index